AJ Loiacono’s healthcare software startup Judi Health reduced costs by 11% for 1,800 plan members and cut claims processing times from more than six months to 18 days. The 53-year-old entrepreneur founded the company, formerly known as Capital Rx, to address inefficiencies in an industry where administrative spending reaches $1 trillion annually, Forbes reported.
Judi Health on Tuesday announced a $400 investment, including a $252 million Series F funding round led by Wellington Management and General Catalyst that doubled the company’s valuation to $3.25 billion. The funding round is set to close in October.
Notable investors include Goldman Sachs Asset Management and Generation Investment Management, chaired by former Vice President Al Gore, Forbes reported.
Don’t Miss:
Loiacono previously co-founded pharmacy benefits consulting firm Truveris, where he spent eight years as a top executive and CEO, witnessing American drug pricing’s deep dysfunction firsthand, Forbes reported. He launched Capital Rx with colleagues Ryan Kelly, now Judi Health’s chief technology officer, and Joseph Alexander in 2017.
The company developed Judi, a modular cloud-based software that cuts through pricing opacity with transparency. Rather than playing pricing games, Capital Rx charges flat administrative fees on either a per-member monthly basis or per-claim structure, according to the outlet. Drug prices get set using the publicly available national average drug acquisition cost database maintained by federal centers for Medicare and Medicaid services.
This approach helped build a substantial pharmacy benefit management business expecting $3.7 billion in revenue this year, up over 75% from last year’s $2.1 billion, Forbes reported. The technology handles the administrative work of claims, but the company does not take on the risk of paying for them.
Trending: Backed by $300M+ in Assets and Microsoft’s Climate Fund, Farmland LP Opens Vital Farmland III to Accredited Investors
U.S. pharmacy spending increased by $50 billion in 2024 to $487 billion at net manufacturer prices, driven by growth in oncology, immunology, cardiovascular, obesity, and diabetes drugs, with GLP-1 therapies such as Ozempic and Wegovy cited by PwC as key inflators.
“The mission of our company is to give our country the infrastructure we need to get the healthcare we deserve,” Loiacono told Forbes. “Until we get control over that infrastructure and modernize it, we can’t begin to advance care in this country.”
The dysfunction runs deeper than most realize, according to the outlet. Medical benefits and prescription coverage operate through completely separate channels, creating duplication, higher costs, and massive frustration for doctors and patients. Drug pricing represents a particular maze of rebates, clawbacks, and fees layered upon fees.
PwC projects the 2026 medical cost trend at 8.5% for the group market and 7.5% for the individual market, and restates 2024 and 2025 trends higher than previously projected.
See Also: Shaquille O’Neal Wants People to Take Heart Health Seriously — This AI-ECG Could Make That Easier
The real prize lies in medical benefits, a far larger market than pharmacy coverage, according to Forbes. Combining medical and pharmacy claims represents healthcare’s holy grail, eliminating industry duplication and administrative waste.
“They are building what we believe is the first unified claims system, which is a huge shift in how benefits are administered,” General Catalyst Managing Director Holly Maloney said. “We think there’s absolutely a $20 billion business to be built here.”
Judi Health has already signed major employer plans and a third-party administrator licensing its technology, representing 40,000 lives for the new health administration product, Forbes reported.
Judi Health on Wednesday announced a multiyear partnership with the Charlotte Hornets, becoming the NBA team’s exclusive jersey patch sponsor ahead of its Oct. 22 home opener against the Brooklyn Nets.
Read Next: 7 Million Gamers Already Trust Gameflip With Their Digital Assets — Now You Can Own a Stake in the Platform
Image: Shutterstock
Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.
Get the latest stock analysis from Benzinga?
This article Former Truveris CEO AJ Loiacono’s Judi Health Hits $3.25B Valuation With $252M Raise To Fix Drug Pricing Chaos originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Source link
